BioNTech - Povijest promjena

WikiSysop: bnz

2022-04-28T10:35:25Z

bnz

←Starija inačica		Inačica od 10:35, 28. travnja 2022.
Redak 1:		Redak 1:
	~~<!--'''BioNTech'''-->~~{{strojni prijevod}}		{{strojni prijevod}}
	{{stil}}		{{stil}}
	{{Tvrtka\|ime=BioNTech SE\|slika=[[Datoteka:BioNTech Logo.png\|200 px]]\|vrsta=Javna tvrtka\|osnutak=2008.\|osnivači=Uğur Şahin,		{{Tvrtka\|ime=BioNTech SE\|slika=[[Datoteka:BioNTech Logo.png\|200 px]]\|vrsta=Javna tvrtka\|osnutak=2008.\|osnivači=Uğur Şahin,

WikiSysop: file u datoteka

2022-04-15T03:41:08Z

file u datoteka

←Starija inačica		Inačica od 03:41, 15. travnja 2022.
Redak 1:		Redak 1:
	<!--'''BioNTech'''-->{{strojni prijevod}}		<!--'''BioNTech'''-->{{strojni prijevod}}
	{{stil}}		{{stil}}
	{{Tvrtka\|ime=BioNTech SE\|slika=[[~~File~~:BioNTech Logo.png\|200 px]]\|vrsta=Javna tvrtka\|osnutak=2008.\|osnivači=Uğur Şahin,		{{Tvrtka\|ime=BioNTech SE\|slika=[[Datoteka:BioNTech Logo.png\|200 px]]\|vrsta=Javna tvrtka\|osnutak=2008.\|osnivači=Uğur Şahin,
	Özlem Türeci,		Özlem Türeci,
	Christoph Huber,		Christoph Huber,

WikiSysop: Bot: Automatska zamjena teksta (-{{Cite web +{{Citiranje weba)

2022-01-02T02:16:17Z

Bot: Automatska zamjena teksta (-{{Cite web +{{Citiranje weba)

WikiSysop: Bot: Automatska zamjena teksta (-{{cite web +{{Citiranje weba)

2021-12-21T23:53:49Z

Bot: Automatska zamjena teksta (-{{cite web +{{Citiranje weba)

Prikaži promjene

WikiSysop: Bot: Automatski unos stranica

2021-12-11T09:44:03Z

Bot: Automatski unos stranica

Nova stranica

{{strojni prijevod}}
{{stil}}
{{Tvrtka|ime=BioNTech SE|slika=[[File:BioNTech Logo.png|200 px]]|vrsta=Javna tvrtka|osnutak=2008.|osnivači=Uğur Şahin,
Özlem Türeci,
Christoph Huber,
Andreas Strüngmann,
Thomas Strüngmann,
Michael Motschmann,
Helmut Jeggle|sjedište=[[Mainz]], [[Njemačka]]|ključne_osobe=Uğur Şahin,
Özlem Türeci,
Sean Marett,
Sierk Poetting,
Ryan Richardson|industrija=Biotehnologija|prihod=121.5 mil EUR (2019.)|proizvodi=BNT162b2 (Cjepivo protiv COVID-19)|operativni_prihod=181.5 mil EUR (2019.)|neto_dobit=179.2 mil EUR (2019.)|zaposleni=1.323 (2019.)|web=[https://biontech.de/ biontech.de]}}

'''BioNTech SE''' ili '''BioNTech''' je [[njemačka]] [[tvrtka]] za [[Biotehnologija|biotehnologiju]] sa sjedištem u [[Mainz|Mainzu]] koja razvija i proizvodi aktivne [[Imunoterapija|imunoterapije]] za pristupe liječenju [[Bolest|bolesti]] specifične za [[Pacijent|pacijenta]]. Razvija [[Farmacija|farmaceutske]] kandidate na bazi [[Ribonukleinska kiselina|ribonukleinske kiseline]] ([[MRNK|mRNA]]) za uporabu kao individualizirane imunoterapije [[Rak (bolest)|raka]], kao [[Cjepivo|cjepiva]] protiv zaraznih bolesti i kao nadomjesne terapije proteina za rijetke bolesti, a također je osmislio i staničnu terapiju, nova [[Protutijela|antitijela]] i imunomodulatore malih [[molekula]] kao mogućnosti liječenja raka.

Tvrtka je razvila humanu terapiju na osnovi mRNA za intravensku primjenu kako bi u klinička ispitivanja dovela individualiziranu imunoterapiju raka na osnovi mRNA i uspostavila vlastiti proizvodni postupak.<ref name="SEC report">{{Citation|language=en|author=BioNTech SE|url=https://sec.report/Document/0001193125-19-241112/|title=Form F-1|publisher=[[United States Securities and Exchange Commission|U.S. Securities and Exchange Commission]]|date=9 September 2019|access-date=23 September 2020}}</ref>

Godine 2020. BioNTech je zajedno s [[Pfizer|Pfizerom]] razvio [[Cjepivo protiv COVID-19|RNK cjepivo BNT162b2]] za sprečavanje infekcija [[COVID-19]], koje nudi 95% učinkovitost.<ref>https://www.fda.gov/media/144245/download</ref> Vlada [[Ujedinjeno Kraljevstvo|Ujedinjenog Kraljevstva]] odobrila je [[2. prosinca]] [[2020.]] privremeno odobrenje za HMR za cijepljenje BNT162b2 u Velikoj Britaniji. Bilo je to prvo mRNA cjepivo ikad odobreno. Nekoliko dana kasnije, cjepivo je također hitno odobreno u [[Sjedinjene Američke Države|Sjedinjenim Državama]],<ref>{{Citation|language=en|title=Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions|url=https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/pfizer-biontech-covid-19-vaccine-frequently-asked-questions|access-date=22 December 2020}}</ref> [[Kanada|Kanadi]],<ref>{{Citation|language=en|title=Pfizer-BioNTech COVID-19 vaccine: What you should know|url=https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/pfizer-biontech.html|access-date=22 December 2020}}</ref> i [[Švicarska|Švicarskoj]].<ref>{{Citation|language=en|title=Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland|url=https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/covid-19-impfstoff_erstzulassung.html|access-date=22 December 2020}}</ref> Europska komisija je [[21. prosinca]] 2020. odobrila BioNTech / Pfizerovo cjepivo protiv [[Koronavirus|koronavirusa]] u skladu s pozitivnom preporukom Europske agencije za lijekove (EMA).<ref>{{Cite web|url=https://www.politico.eu/article/european-commission-approves-biontech-pfizer-vaccine/|title=Commission approves BioNTech/Pfizer vaccine|date=2020-12-21|website=POLITICO|language=en-US|access-date=2020-12-22}}</ref>

== Povijest ==

=== Temelj i razvoj (2008. - 2013.) ===
BioNTech je osnovan [[2008.]] godine na temelju istraživanja [[Uğur Şahin|Uğura Şahina]], [[Özlem Türeci|Özlema Türecija]],<ref>{{Cite web|url=https://www.france24.com/en/live-news/20201113-biontech-s-founders-scientist-couple-in-global-spotlight|title=BioNTech's founders: scientist couple in global spotlight|date=2020-11-13|website=France 24|language=en|access-date=2020-12-22}}</ref> i Christoph Hubera,<ref name="browne">{{cite news|author1=Ryan Browne|title=What you need to know about BioNTech — the European company behind Pfizer's Covid-19 vaccine|url=https://www.cnbc.com/2020/11/11/biontech-the-european-company-behind-pfizers-covid-19-vaccine.html|access-date=7 December 2020|work=CNBC|date=11 November 2020}}</ref> s početnim ulaganjem od 150 milijuna [[Euro|eura]].<ref>{{Cite web|url=https://investors.biontech.de/node/6751/html#toc|title=SEC Filing {{!}} BioNTech|website=investors.biontech.de|access-date=2020-12-28}}</ref> Djelatnosti tvrtke usmjerene su na razvoj i proizvodnju tehnologija i lijekova za individualiziranu imunoterapiju raka.<ref name="SEC report" /> Andreas i Thomas Strüngmann, Michael Motschmann i Helmut Jeggle bili su suosnivači.<ref name="france24">{{cite news|title=BioNTech's founders: scientist couple in global spotlight|url=https://www.france24.com/en/live-news/20201113-biontech-s-founders-scientist-couple-in-global-spotlight|access-date=7 December 2020|work=France24|date=13 November 2020}}</ref> [[2009.]] godine dogodila se [[Akvizicija poduzeća|akvizicija]] EUFETS i JPT Peptide Technologies.<ref>{{Citation|language=en|url=https://www.biontech-imfs.de/news-events/news-post/news/eufets-becomes-biontech-innovative-manufacturing-services/|title=Eufets Becomes BioNTech Innovative Manufacturing Services|publisher=BioNTech IMFS|date=18 September 2017|access-date=11 November 2020}}</ref><ref>{{cite web|url=https://www.genomeweb.com/proteomics/theracode-acquire-jpt-peptide-technologies#.X85h3NhKhnI|title=TheraCode to Acquire JPT Peptide Technologies|date=11 May 2009|publisher=GenomeWeb|access-date=7 December 2020}}</ref> [[2013.]] godine Katalin Karikó pridružila se tvrtki BioNTech kao viša potpredsjednica.<ref>{{Cite web|url=https://forbes.hu/uzlet/hanyatatott-sorsu-magyar-szabadalom-is-kellett-a-most-bejelentett-vakcinahoz/|title=Magyar kutató, hányatatott sorsú szabadalma is kellett a most bejelentett vakcinához {{!}} Forbes.hu|date=2020-11-09|website=forbes.hu|language=hu|access-date=2020-12-22}}</ref>

=== Proširenje (2014. - 2019.) ===
Između [[2014.]] i [[2018.]] godine, BioNTech je objavio mnoge rezultate istraživanja mehanizama mRNA.<ref>{{Citation|language=en|last1=Kranz|first1=Lena M.|last2=Diken|first2=Mustafa|last3=Haas|first3=Heinrich|last4=Kreiter|first4=Sebastian|last5=Loquai|first5=Carmen|title=Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy|newspaper=Nature|volume=534|issue=7607|date=16 June 2016|issn=1476-4687|pages=396–401|url=https://pubmed.ncbi.nlm.nih.gov/27281205/|access-date=11 November 2020|doi=10.1038/nature18300|pmid=27281205|bibcode=2016Natur.534..396K}}</ref> Programi suradnje i komercijalizacije zaključeni su s raznim tvrtkama i znanstvenim institucijama počevši od [[2015.]]<ref>{{cite web|url=https://www.fiercebiotech.com/biotech/genentech-lays-310-million-wager-biontech-s-mrna-cancer-vaccine-platform|title=Genentech lays $310M wager on BioNTech's mRNA cancer vaccine platform|date=21 September 2016|publisher=FierceBiotech|access-date=7 December 2020|author1=Nick Paul Taylor}}</ref> Tijekom tog razdoblja, BioNTech je podnio nekoliko patentnih prijava i razvio višeslojnu strategiju zaštite svog intelektualnog vlasništva na različitim tehnološkim platformama i njihovu primjenu u liječenju raka i drugih ozbiljnih bolesti.

U [[Rujan|rujnu]] [[2019.]] BioNTech je primio kapitalno ulaganje od 55 milijuna [[Američki dolar|američkih dolara]] od Zaklade Bill & Melinda Gates, s mogućnošću da taj iznos ulaganja naknadno udvostruči.<ref>{{Cite web|url=https://investors.biontech.de/news-releases/news-release-details/biontech-announces-new-collaboration-develop-hiv-and|title=BioNTech Announces New Collaboration to Develop HIV and Tuberculosis Programs|date=2019-09-04|publisher=BioNTech|access-date=2020-12-27}}</ref>

Od [[10. listopada]] [[2019.]] godine, BioNTech, sa svojim novoosnovanim sjedištem u [[Sjeverna Amerika|Sjevernoj Americi]] u [[Cambridge, Massachusetts|Cambridgeu]], Massachusetts, javno se trguje kao američka depozitarna dionica (ADS) na Nasdaq Global Select Marketu pod oznakom BNTX.<ref>{{Citation|language=en|url=https://www.nasdaq.com/market-activity/stocks/bntx|title=BioNTech SE|publisher=Nasdaq|access-date=12 November 2020}}</ref> BioNTech je uspio ostvariti ukupan bruto prihod od 150 milijuna dolara od IPO-a.<ref name="spalding">{{cite news|last1=Spalding|first1=Rebecca|last2=Franklin|first2=Joshua|title=Germany's BioNTech raises $150 million in smaller-than-planned U.S. IPO amid market volatility|url=https://www.reuters.com/article/us-biontech-ipo-idUSKBN1WO29B|access-date=7 December 2020|work=Reuters|date=9 October 2019}}</ref>

== Ulaganja ==
U [[Prosinac|prosincu]] 2019. BioNTech je dobio 50 milijuna eura financiranja od Europske investicijske banke u sklopu Plana ulaganja Europske komisije za [[Europa|Europu]].<ref name="PR December 17, 2019">{{cite web|url=https://ec.europa.eu/commission/presscorner/detail/en/IP_19_6796|title=European Investment Bank provides funding of €50 million to BioNTech as part of the Investment Plan for Europe|author=|date=17 December 2019|language=en|publisher=[[European Commission]]|access-date=21 November 2020}}</ref>

U [[Lipanj|lipnju]] 2020. godine BioNTech je dobio 250 milijuna eura od Temasek Holdings ([[Singapur]]) kupnjom običnih dionica i četverogodišnjih konvertibilnih novčanica,<ref>{{cite news|last=Burger|first=Ludwig|date=29 June 2020|title=Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech|url=https://www.reuters.com/article/us-biontech-placement/temasek-led-investor-group-in-250-million-vaccine-bet-on-germanys-biontech-idUSKBN2400PS|work=[[Reuters]]|location=[[Frankfurt]]|access-date=2 August 2020}}</ref> ali i od drugih investitora privatnim plasiranjem obveznih konvertibilnih obveznica. Također je od Europske investicijske banke primila 100 milijuna eura za financiranje duga.<ref name="PR June 11, 2020">{{cite web|url=https://ec.europa.eu/commission/presscorner/detail/en/ip_20_1034|title=Investment Plan for Europe: European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing|author=|date=11 June 2020|language=en|publisher=[[European Commission]]|access-date=21 November 2020}}</ref>

== Lokacije ==
Mjesto osnivanja i globalnog sjedišta BioNTecha je Mainz, Njemačka. Tvrtka vodi više lokacija u gradu. Daljnja istraživačka mjesta nalaze se u [[San Diego, Kalifornija|San Diegu]] i Cambridgeu (Massachusetts) sa sjedištem u Sjevernoj Americi.

Uz to, tvrtka posjeduje GMP certificirane proizvodne pogone u [[Idar-Oberstein|Idar-Obersteinu]], [[Martinsried|Martinsriedu]], Neuriedu i [[Berlin|Berlinu]]. U [[Studeni|studenom]] [[2020.]] tvrtka je od Novartisa u Marburgu nabavila pogone za povećanje proizvodnje [[Cjepivo protiv COVID-19|cjepiva]].

== Razvoj cjepiva ==
{{Glavni|Cjepivo protiv COVID-19}}
[[Datoteka:Covid19_vaccine_biontech_pfizer_3.jpg|mini|Tozinameran (Pfizer-BioNTech COVID-19 cjepivo)]]

Projekt razvoja nove mRNA tehnologije za cjepivo COVID-19 nazvan je "Projekt Lightspeed", koji je započeo sredinom [[Siječanj|siječnja]] 2020. godine, samo nekoliko dana nakon što je genetska sekvenca [[SARS-CoV-2]] prvi put objavljena u javnosti.<ref>{{cite web|url=https://biontech.de/covid-19|title=Aiming to address the global coronavirus pandemic: Project Lightspeed|date=2020|publisher=BioNTech|access-date=13 December 2020}}</ref> [[Tvrtka]] radi na razvoju tozinameran RNA cjepiva s [[Pfizer|Pfizerom]]<ref>{{cite news|last=Lovelace Jr.|first=Berkeley|date=27 July 2020|title=Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday|url=https://www.cnbc.com/2020/07/27/pfizer-and-biontech-began-late-stage-human-trial-for-coronavirus-vaccine-monday.html|work=[[CNBC]]|access-date=2 August 2020}}</ref> i [[Fosun|Fosunom]].<ref>{{cite news|author=|title=BioNTech in China alliance with Fosun over coronavirus vaccine candidate|url=https://www.reuters.com/article/biontech-fosunpharma-vaccine-collaborati/biontech-in-china-alliance-with-fosun-over-coronavirus-vaccine-candidate-idUSL8N2B90UW|work=[[Reuters]]|location=[[Frankfurt]]|date=15 March 2020|access-date=2 August 2020}}</ref><ref>{{cite news|last=Burger|first=Ludwig|title=Germany approves trials of COVID-19 vaccine candidate|url=https://www.reuters.com/article/us-health-coronavirus-vaccine-biontech/germany-approves-trials-of-covid-19-vaccine-candidate-idUSKCN2241DN|work=[[Reuters]]|location=[[Berlin]]|date=22 April 2020|access-date=2 August 2020}}</ref>

Proizvodnju cjepiva slijedila su klinička ispitivanja čiji je uspjeh bio preduvjet za početak stavljanja na tržište. [[9. studenoga|9. studenog]] 2020. BioNTech i Pfizer objavili su da je 43.500 ljudi u 6 zemalja dobilo testno cjepivo protiv [[COVID-19]], a klinička ispitivanja imala su više od 90 posto učinkovitosti. Na temelju uspješnog testiranja zatražili su pravo distribucije cjepiva u [[SAD|Sjedinjenim Državama]], kao i u [[Europska unija|Europskoj uniji]], [[Ujedinjeno Kraljevstvo|Ujedinjenom Kraljevstvu]] i [[Japan|Japanu]].<ref>{{Cite news|date=2020-11-09|title=Covid vaccine: First 'milestone' vaccine offers 90% protection|language=en-GB|work=BBC News|url=https://www.bbc.com/news/health-54873105|access-date=2020-12-22}}</ref>

=== Distribucija ===
BioNTech i [[Pfizer]] potpisali su ugovore o isporuci 300 milijuna doza cjepiva protiv [[SARS-CoV-2]] za Europsku uniju,<ref>{{cite news|date=11 November 2020|title=Coronavirus: EU buys 300m doses of BioNTech-Pfizer vaccine|work=[[BBC News]]|location=[[United Kingdom]]|url=https://www.bbc.co.uk/news/world-europe-54902056|access-date=12 November 2020}}</ref> 120 milijuna doza za Japan,<ref>{{cite news|last1=Shakil|first1=Ismail|last2=Mishra|first2=Manas|date=31 July 2020|title=Pfizer, BioNTech to supply 120 million doses of coronavirus vaccine to Japan|url=https://www.reuters.com/article/us-health-coronavirus-japan-pfizer-biont/pfizer-biontech-to-supply-120-million-doses-of-coronavirus-vaccine-to-japan-idUSKCN24W1CY|work=[[Reuters]]|location=[[Bengaluru]]|access-date=3 August 2020}}</ref> 100 milijuna doza za Sjedinjene Države<ref>{{cite news|last1=Erman|first1=Michael|last2=Banerjee|first2=Ankur|date=22 July 2020|title=U.S. to pay Pfizer, BioNTech $1.95 billion for COVID-19 vaccine|url=https://www.reuters.com/article/us-health-coronavirus-usa-pfizer/u-s-to-pay-pfizer-biontech-1-95-billion-for-covid-19-vaccine-idUSKCN24N1I9|work=[[Reuters]]|access-date=2 August 2020}}</ref> i 40 milijuna doza za Ujedinjeno Kraljevstvo,<ref>{{cite news|last=Gallagher|first=James|date=20 July 2020|title=Coronavirus vaccine: UK government signs deals for 90 million doses|url=https://www.bbc.com/news/health-53469269|work=[[BBC News]]|access-date=2 August 2020}}</ref><ref>{{cite news|last=Smout|first=Alistair|date=20 July 2020|title=Britain secures 90 million possible COVID-19 vaccine doses from Pfizer/BioNTech, Valneva|url=https://www.reuters.com/article/us-health-coronavirus-britain-vaccines/britain-secures-90-million-possible-covid-19-vaccine-doses-from-pfizer-biontech-valneva-idUSKCN24L0GN|work=[[Reuters]]|location=[[London]]|access-date=2 August 2020}}</ref> ako se pokaže učinkovitim, sigurnim i licenciranim.

Dana [[10. studenoga]] [[2020.]] nakon pozitivne privremene analize faze III kliničkog ispitivanja u Sjedinjenim Državama, partneri BioNTech-Pfizer podnijeli su zahtjev za hitnua uporabu s FDA-om, koji bi trebao pregledati prijavu do sredine prosinca.<ref name="FDA PR 20201120">{{cite press release|title=Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss COVID-19 Vaccine Candidate|website=U.S. [[Food and Drug Administration]] (FDA)|url=https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-announces-advisory-committee-meeting-discuss-covid-19-vaccine|access-date=20 November 2020}} {{PD-notice}}</ref><ref name="stat11-20">{{cite web|url=https://www.statnews.com/2020/11/20/pfizer-biontech-submit-formal-application-to-fda-to-authorize-covid-19-vaccine/|title=Pfizer, BioNTech submit formal application to FDA to authorize Covid-19 vaccine|date=20 November 2020|publisher=STAT|access-date=25 November 2020|author1=Helen Branswell}}</ref> FDA je objavila dokument u kojem se objašnjava da je EUA "mehanizam koji olakšava dostupnost i upotrebu medicinskih protumjera, uključujući cjepiva, tijekom hitnih slučajeva u javnom zdravstvu, poput trenutne [[Pandemija COVID-19|pandemije COVID-19]]".<ref name="fda-eua">{{cite web|url=https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained|title=Emergency Use Authorization for Vaccines Explained|date=20 November 2020|website=U.S. [[Food and Drug Administration]]|access-date=20 November 2020}} {{PD-notice}}</ref> U studenom je Pfizer predao EUA prijavu u [[Kanada|Kanadi]].<ref name="dangerfield">{{cite news|author1=Katie Dangerfield|title=Pfizer files for emergency use of coronavirus vaccine in U.S. — what about in Canada?|url=https://globalnews.ca/news/7474273/pfizer-emergency-use-coronavirus-vaccine-canada/|access-date=25 November 2020|work=Global News|date=20 November 2020}}</ref>

[[Ujedinjeno Kraljevstvo]] je [[2. prosinca]] 2020. odobrilo uvjetnu privremenu dozvolu (prema Uredbi 174 Propisa o humanim lijekovima iz [[2012.]]) za BNT162b2,<ref name="uk12-2a">{{cite web|url=https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/940728/Conditions_of_Authorisation_for_Pfizer_BioNTech_COVID-19_vaccine.pdf|title=Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine|date=2 December 2020|language=en|publisher=Government of the United Kingdom|access-date=2 December 2020}}</ref> postavši prva država koja je odobrila mRNA cjepivo i prva zapadna država koja je odobrila [[cjepivo protiv COVID-19]] za nacionalnu upotrebu.<ref name="uk12-2">{{cite web|url=https://www.gov.uk/government/news/uk-medicines-regulator-gives-approval-for-first-uk-covid-19-vaccine|title=UK medicines regulator gives approval for first UK COVID-19 vaccine|date=2 December 2020|language=en|publisher=Government of the United Kingdom|access-date=2 December 2020}}</ref><ref>{{Cite news|date=2 December 2020|title=Covid Pfizer vaccine approved for use next week in UK|first=Michelle|last=Roberts|language=en-GB|work=[[BBC]]|url=https://www.bbc.com/news/health-55145696|access-date=2 December 2020}}</ref> BNT162b2 bio je na procjeni tijekom prosinca za status odobrenja za hitnu uporabu (EUA) u nekoliko drugih zemalja.<ref name="mueller">{{cite news|author1=Benjamin Mueller|title=U.K. Approves Pfizer coronavirus vaccine, a first in the West|url=https://www.nytimes.com/2020/12/02/world/europe/pfizer-coronavirus-vaccine-approved-uk.html|access-date=2 December 2020|work=The New York Times|date=2 December 2020}}</ref>

[[Europska agencija za lijekove]] (EMA) odobrila je jednogodišnju uvjetnu uporabu cjepiva BioNTech / Pfizer u Europskoj uniji [[21. prosinca]] 2020. Emer Cooke, direktor EMA-e, izjavio je da blagodati cjepiva daleko premašuju potencijalne rizike. Cijena doze cjepiva BioNTech / Pfizer iznosi 12 EUR (za usporedbu ovo košta više od četiri od njegovih budućih pet konkurenata: Oxford / AstraZeneca: 1,78 EUR; Johnson & Johnson: 8,50 EUR; [[Sanofi]] / GSK: 7,56 EUR; CureVac : 10 eura, ali Modernina cjepiva su skuplja i koštaju 18 eura.)<ref>{{Cite web|url=https://www.politico.eu/article/belgian-secretary-of-state-accidentally-reveals-eu-vaccine-prices/|title=Belgian secretary of state accidentally reveals EU vaccine prices|date=2020-12-17|website=POLITICO|language=en-US|access-date=2020-12-22}}</ref> Prema sporazumu, par koji proizvodi cjepivo, BioNTech i Pfizer, podliježe strožoj zakonskoj obvezi da sve stečeno iskustvo EMA-i donesu za pregled.<ref>{{Cite web|url=https://koronavirus.gov.hu/cikkek/az-europai-gyogyszerugynokseg-forgalmazasra-ajanlja-pfizerbiontech-vakcinat|title=Az Európai Gyógyszerügynökség forgalmazásra ajánlja a Pfizer/BioNTech-vakcinát|date=2020-12-21|website=koronavirus.gov.hu|language=hu|access-date=2020-12-22}}</ref>

Nakon odobrenja, masovno cijepljenje protiv koronavirusa započelo je prvi put u [[Mađarska|Mađarskoj]] i [[Slovačka|Slovačkoj]] u [[Europska unija|Europskoj uniji]] [[26. prosinca]] 2020.<ref>{{Cite news|last=Binnie|first=Anita Komuves, Benoit Van Overstraeten, Isla|date=2020-12-27|title='Window of hope': Europe begins to launch COVID-19 vaccinations|language=en|work=Reuters|url=https://www.reuters.com/article/health-coronavirus-europe-vaccines-idUSKBN29102Y|access-date=2020-12-27}}</ref>

== Vidi još ==

* [[Pfizer]]
* [[Biotehnologija]]

== Izvori ==
{{Izvori}}

[[Kategorija:Njemačke tvrtke]]